Author:
Pham Thao,Bachelez Hervé,Berthelot Jean-Marie,Blacher Jacques,Claudepierre Pascal,Constantin Arnaud,Fautrel Bruno,Gaujoux-Viala Cécile,Goëb Vincent,Gossec Laure,Goupille Philippe,Guillaume-Czitrom Séverine,Hachulla Eric,Lequerré Thierry,Marolleau Jean-Pierre,Martinez Valérie,Masson Charles,Mouthon Luc,Puéchal Xavier,Richette Pascal,Saraux Alain,Schaeverbeke Thierry,Soubrier Martin,Viguier Manuelle,Vittecoq Olivier,Wendling Daniel,Mariette Xavier,Sibilia Jean
Reference128 articles.
1. Time to treatment response with abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate;Kremer;Arthritis Rheum,2008
2. Time to treatment response with abatacept in patients with RA and an inadequate response to anti-TNF therapy;Schiff;Arthritis Rheum,2008
3. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor inhibition;Genovese;N Engl J Med,2005
4. Long-term safety of abatacept: integrated analysis of clinical program data of up to 7 years of treatment;Hochberg;Arthritis Rheum,2010
5. EMA - Scientific discussion for Orencia - London, 21 May 2010.